| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Strategic Planning > On the Job Preliminary Threat Assessment |
|
Digg It - On the Job Preliminary Threat Assessment
The FBI’s Threat Assessment for work place suggests asking the following questions of individuals who are awar According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product e of a workforce offenders habits in order to determine the level of risk for violence from that individual. A ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in s a result of the answers to these questions the potential risk factor can be assessed and an intervention pla lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. n can be created. · What has happened in the offender’s life that may have prompted what is perceived as thre here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe atening? What comments has the offender made to family or coworkers? · What does the offender think of their d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro self in relationship to all others? · Does the offender feel offended by someone else? · Is the offender an ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc individual who takes responsibility for their actions? · How does the offender handle disappointment, loss or easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi failures in their life? · What is the interface of the offender with their co-workers? · Does the offender nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically feel the company is fair in their treatment of them? · Are the offender experiencing difficulties with superv and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ isors or management? · Is the offender demonstrating concern with job responsibilities and practices? · Has ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi the offender been written up for unfavorable job performance or corrected by management? · Are there personal ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a traumas in the offender’s life as a death or problems effecting family, health, romance, finances, debts, and dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod bankruptcy? · Does evidence point to offender’s substance abuse, depression or mental illness? · Is the off cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ender demonstrating an interest in violence through movies, games, books, or magazines? · Is the offender pre tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen occupied with violence or showing interest in publicized violent events; or fascination with and/or recently a t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel cquired weapons? · Has the offender stated to others that they have selected a particular target for their vi ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust olence?
· Does the offender have an obsession with someone or are stalking and surveillance involved?
· Ha y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products s the offender spoken of personal injury to themselves or others? · Does the offender have a criminal record . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de or demonstrated violence in the past? · Has the offender expressed a plan or method of how they will enact vi elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip olence? · Does the plan sound reasonable and specific? · Is the offender capable of carrying out their plan? tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Enterprise Content Management: Convergence of Structured & Unstructured Data Management 5 New Year Resolutions for Business Growth
|